Canadian Paediatric Surveillance Program: Two years of a system for investigating unusual paediatric disorders

P Sockett1

  • 1Division of Disease Surveillance, Bureau of Infectious Diseases, Laboratory Centre for Disease Control, Ottawa, Ontario.

Insights

The Canadian Paediatric Surveillance Program (CPSP) monitors rare childhood diseases. It collects data from pediatricians across Canada to track public health conditions.

Area of Science:

  • Pediatrics
  • Public Health
  • Epidemiology

Background:

  • The Canadian Paediatric Surveillance Program (CPSP) was established in 1996.
  • It is a collaboration between the Canadian Paediatric Society (CPS) and the Laboratory Centre for Disease Control (LCDC).
  • Oversight is provided by a steering committee with expertise in paediatrics, epidemiology, genetics, and public health.

Purpose of the Study:

  • To actively surveil rare and unusual paediatric conditions of public health importance in Canada.
  • To collect timely data on the incidence of specific paediatric diseases.
  • To facilitate research and collaboration on childhood health issues.

Main Methods:

  • Monthly report cards were sent to all clinically active paediatricians in Canada.
  • Paediatricians reported the number of new cases for selected conditions, including nil reports.
  • Detailed case report forms were used for follow-up, with data analyzed by principal investigators.

Main Results:

  • In its initial two years, the program reported on seven rare paediatric conditions.
  • The system successfully gathered data on paediatric disease incidence through active reporting.
  • The program demonstrated feasibility for ongoing surveillance of public health priorities.

Conclusions:

  • The CPSP is an effective active surveillance system for rare paediatric conditions in Canada.
  • The program's methodology allows for the monitoring of public health concerns in children.
  • Future plans include international collaboration and expansion of surveillance capabilities.

Related Concept Videos

Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Principles of Disease Surveillance01:26

Principles of Disease Surveillance

Disease surveillance is the systematic collection, analysis, and interpretation of health data essential to the planning, implementation, and evaluation of public health practice. This process integrates data dissemination to entities responsible for preventing and controlling disease, injury, and disability. Surveillance systems provide crucial information for action, helping public health authorities make informed decisions to manage and prevent outbreaks, ensure public safety, optimize...
Investigation of Disease Outbreaks01:23

Investigation of Disease Outbreaks

Multistate foodborne outbreaks pose significant public health risks and require meticulous investigation to identify sources and implement control measures. The Centers for Disease Control and Prevention (CDC) utilizes a dynamic seven-step process for these investigations, integrating data from laboratories, interviews, and environmental assessments to protect public health.Outbreak Detection: The detection of multistate outbreaks typically begins with PulseNet, the CDC's national laboratory...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...